Business
IDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors
- Dr. Susan L. Kelley was a former clinical development executive in oncology with Bayer and Bristol Myers Squibb, and led the development and regulatory
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"- Dr. Susan L. Kelley was a former clinical development executive in oncology with Bayer and Bristol Myers Squibb, and led the development and regulatory approval of Nexavar®\n\n\nSOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Susan Kelley, M.D., to its Board of Directors. \n\n \n \n \n \n \n \n\n \nDr. Kelley brings over 25 years of experience in oncology drug research and development to IDEAYA. Most recently she served as Chief Medical Officer of the Multiple Myeloma Research Consortium (MMRC) where she led the strategic design and management of clinical trials in North America. Prior to the MMRC, she held positions of increasing responsibility at Bayer Healthcare Pharmaceuticals and Bayer-Schering Pharma, including Vice President, Global Clinical Development and Therapeutic Area Head – Oncology, where she led the team responsible for the development and worldwide regulatory approval of Nexavar® (sorafenib). Prior to joining Bayer, Dr. Kelley worked at Bristol-Myers Squibb in Oncology and Immunology drug development, ultimately serving as Executive Director, Oncology Clinical Research, at the Bristol-Myers Squibb Pharmaceutical Research Institute. She serves or has served as a member of the Board of Directors at multiple publicly traded companies including Deciphera Pharmaceuticals, Daré Bioscience, VBL Therapeutics Ltd, ArQule and Immune Design. Dr. Kelley received her M.D. from Duke University School of Medicine. She was a Fellow in Medical Oncology and Clinical Fellow in Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a Fellow in Medical Oncology and Pharmacology at Yale University School of Medicine, where she also served as a Clinical Assistant Professor of Medicine.\n\"Susan's expertise in clinical oncology will be invaluable as we advance the Phase 1 IDE397 program in MTAP-deletion, evaluate potential Phase 2 expansion for the IDE196 / binimetinib combination, and target to select a Development Candidate for the potential first-in-class PARG Synthetic Lethality program this year,\" said Yujiro S. Hata, President and Chief Executive Officer, at IDEAYA Biosciences. \n\"I am excited to jo...